Indian Journal of Dental ResearchIndian Journal of Dental ResearchIndian Journal of Dental Research
HOME | ABOUT US | EDITORIAL BOARD | AHEAD OF PRINT | CURRENT ISSUE | ARCHIVES | INSTRUCTIONS | SUBSCRIBE | ADVERTISE | CONTACT
Indian Journal of Dental Research   Login   |  Users online:

Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size         

 


 
SYSTEMATIC REVIEWS AND META-ANALYSIS Table of Contents   
Year : 2022  |  Volume : 33  |  Issue : 3  |  Page : 323-331
Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review


1 Department of Oral and Maxillofacial Pathology, Vivekanandha Dental College for Women, Tamil Nadu, India
2 Department of Oral and Maxillofacial Pathology, KSR Institute of Dental Science and Research, Tamil Nadu, India
3 Department of Oral Medicine and Radiology, M.M. College of Dental Sciences and Research, Mullana, Haryana, India
4 Department of Oral and Maxillofacial Pathology, King George Medical College, Uttar Pradesh, India
5 Department of Oral and Maxillofacial Pathology, Vishnu Dental College, Andhra Pradesh, India
6 Department of Oral and Maxillofacial Pathology, Cuddalore Government Dental College and Hospital, Tamil Nadu, India

Correspondence Address:
Dr. Kenniyan K Srichinthu
Associate Professor, Department of Oral Pathology and Microbiology, KSR Institute of Dental Science and Research, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdr.ijdr_456_22

Rights and Permissions

Ameloblastoma is a benign, locally aggressive neoplasm that needs extensive surgical resection. The goal of this article is to obtain an in-depth review of benign ameloblastomas to determine the available level of evidence and the possible benefit of targeted therapeutics for the treatment of ameloblastoma and BRAF V600E mutation in ameloblastoma. An electronic literature search was conducted according to PRISMA guidelines in PubMed/MEDLINE, EBSCO, and Web of Science for eligible studies published between 1975 and 2021. The systematic review is registered with INPLASY (INPLASY202260018). The review included 2 case series and 17 case reports. The histopathological type, anatomic location, expression of BRAF mutation, additional mutations, and molecular-targeted therapies of the 19 reviewed articles were summarized and tabulated. Interestingly, the majority of the primary site of ameloblastoma was located in the mandible (80.9%) compared to the maxilla (17%). The tumour size was reported in nine of the included studies. Most of the included studies in the review exhibited ameloblastoma with BRAF V600E mutations and responded to molecular-targeted therapies. Molecular therapies employing BRAF and/or MEK inhibitors in ameloblastoma with BRAF V600E mutations proved to be an appropriate treatment based on the limited available evidence. It is essential further to deepen our understanding at the clinical and molecular level to enhance the precision of management of ameloblastoma.


[FULL TEXT] [PDF]*
Print this article     Email this article

 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
  Citation Manager
 Access Statistics
  Reader Comments
  Email Alert *
  Add to My List *
 
 

 Article Access Statistics
    Viewed618    
    Printed28    
    Emailed0    
    PDF Downloaded21    
    Comments [Add]    

Recommend this journal